Ioanna Vlachaki

Articles by Ioanna Vlachaki

12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

12 EMERALD Trial Analysis of Patient-Reported Outcomes (PROs) in Patients (pts) With ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) Comparing Oral Elacestrant vs Standard-of-Care (SoC) Endocrine Therapy

ByJavier Cortés, MD,François-Clément Bidard,Aditya Bardia, MD, MPH, FASCO,Virginia G. Kaklamani, MD, DSc,Ioanna Vlachaki,Giulia Tonini,Nassir Habboubi,Philippe Aftimos

August 17th 2024

Latest Updated Articles

Trending on CancerNetwork

MASLD Raises Liver and Other Cancer Risks, Supporting Selective HCC Surveillance

Weighing Immunotherapy for Bridging and Downstaging Before HCC Transplant

What Separates a Next-Generation Liver Tumor Board From the Traditional Model?

BOT+BAL Yields Long-Term Survival in Patients With Refractory MSS mCRC

How Should Liver Function and Patient Values Guide HCC Treatment?